The Insulin Receptor Talks to Glucagon?  by Gromada, Jesper et al.
Cell Metabolism
PreviewsThe Insulin Receptor Talks to Glucagon?
Jesper Gromada,1,* Alokesh Duttaroy,1 and Patrik Rorsman2
1Novartis Institutes for BioMedical Research, 100 Technology Square, Cambridge, MA 02139, USA
2University of Oxford, OCDEM, Churchill Hospital, Oxford OX3 7LJ, UK
*Correspondence: jesper.gromada@novartis.com
DOI 10.1016/j.cmet.2009.03.008
Type 2 diabetes (T2DM) is not only a disorder of impaired insulin secretion but also glucagon oversecretion.
However, the link between the two remains unclear. Is it possible that the latter is a consequence of the
former? In this issue, Kawamori et al. (2009) have addressed this question by generating a cell-specific insulin
receptor knockout mice.Insulin and glucagon are both released
from the pancreatic islets, small endocrine
islands of cells evenly distributed
throughout the exocrine part of the gland.
Glucose stimulates insulin secretion from
islet b cells and thereby increases glucose
storage in several tissues and decreases
glucose production by the liver. Islet a cells
secrete glucagon in response todecreased
blood glucose (hypoglycemia), whereas
elevated glucose levels suppress glucagon
release. Glucagon is the body’s principal
counterregulatory hormone and opposes
the anaboliceffects of insulin bystimulating
glucose production from the liver. A fine
balance between insulin and glucagon
secretion maintains the blood glucose
levels within the narrow physiological
range.
Within human islets, the a and b cells
show a more mixed distribution than is
seen in rodent islets and the a cells are
frequently juxtaposed to the b cells (Cab-
rera et al., 2006). Thus, it is likely that the
a cells will be exposed to high interstitial
insulin concentrations whenever insulin is
secreted. Indeed, there is evidence in
humans (and rodents) that high intraislet
insulin levels lead to inhibition of glucagon
secretion elicited by hyperglycemia (Ba-
narer et al., 2002). This and other observa-
tions have led to the b cell ‘‘switch-off’’
hypothesis, in which the cessation of
insulin secretion from the b cells inhibits
glucagon secretion fromacells. Kawamori
et al. now provide evidence that pancre-
atic a cell insulin receptors modulate
glucagon secretion in vivo. Their results
highlight an important role of intraislet
insulin signaling for control of glucagon
secretion and glucose homeostasis.
Type 2 diabetes (T2DM) mellitus is asso-
ciated with reduced capacity of glucose to
suppress glucagon secretion, and it is likelythat the oversecretion of glucagon exacer-
bates the hyperglycemia resulting from the
lackof insulin. To make thingsworse, india-
betic individuals, hyperglycemia has in fact
been found to exert a paradoxical stimula-
tory effect on glucagon secretion (Dunning
and Gerich, 2007). It is tempting to ascribe
the latter defects to the inadequate insulin
secretion with the resultant loss of the
‘‘switch-off’’ mechanism (Figure 1). A large
body of literature (summarized in Gromada
et al., 2007) implicates insulin/insulin
signaling as an important player in the
systemic regulation of glucagon secretion.
Indeed, the transcripts encoding the insulin
receptor as well as the downstream
signaling elements are present in pancre-
atic a cells at levels comparable to those
found in the liver (Franklin et al., 2005).
Kawamori et al. studied the role of
insulin signaling in glucagon secretion by
creating a mouse model in which the
insulin receptor had been selectively
ablated in the a cell (aIRKO). aIRKO mice
exhibit mild fasting hyperglycemia but
become markedly hyperglycemic and hy-
perglucagonemic upon feeding. Whole-
pancreas perfusion experiments further
demonstrate increased arginine-induced
glucagon secretion in aIRKO mice (argi-
nine stimulates both insulin and glucagon
secretion), an effect that would indeed
be consistent with the idea that insulin
signaling normally exerts a suppressor
effect on glucagon release.
Kawamori et al. also compared
glucagon levels in wild-type and knockout
mice following the selective destruction of
the b cells by the cytotoxic agent strepto-
zotocin. In both wild-type and aIRKO
mice, streptozotocin-induced diabetes
was associated with increased plasma
glucagon levels. The observation that
plasma glucagon levels in aIRKO miceCell Metabodid not increase beyond those seen in
control mice following destruction of the
b cells provides additional support of the
concept that plasma insulin levels plays
suppressor function in the long-term regu-
lation of glucagon secretion. It will be inter-
esting to investigate the effects of insulin
treatment on glucagon secretion in strep-
tozotocin-treated aIRKO. Such a model
might better reflect the situation in
patients with diabetes, a condition when
the a cells may be exposed to high exoge-
nous insulin levels for many decades.
How do these findings fit into current
concepts of metabolic control of glucagon
secretion? Recent investigations have
shown that insulin inhibits glucagon secre-
tion by inhibition of a cell electrical activity
and lowering of cytoplasmic [Ca2+]
(Figure 2). These effects have been attrib-
uted to membrane hyperpolarization by
activation of ATP-regulated K+ channels
(KATP channels) (Franklin et al., 2005) and/
or to recruitment of GABAA receptor Cl

channels to the plasma membrane (Xu
et al., 2006) (GABA being coreleased with
insulin from the b cells [Braun et al., 2007])
(Figure 2). In addition to the paracrine regu-
lation mediated by insulin as well as other
factors released within the pancreatic islets
(like Zn2+ and somatostatin; reviewed by
Gromada et al., 2007), it appears that
glucagon secretion is also under intrinsic
control (i.e., within the a cell itself; Rorsman
et al., 2008). The significance of such
mechanisms is in fact convincingly demon-
strated by Kawamori et al. in studies where
they used the hyperinsulinemic-hypogly-
cemic clamp technique. Under these
experimental conditions hypoglycemia is
induced by infusion of high insulin concen-
tration. Interestingly, hypoglycemia-
induced glucagon secretion was 60%
higher in the aIRKO than in wild-typelism 9, April 8, 2009 ª2009 Elsevier Inc. 303
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PreviewsFigure 1. Plasma Insulin, Glucagon, and Glucose Levels in Response to a Meal in Healthy Individual and Patients with T2DM
Blood glucose levels are regulated by carefully orchestrated changes of insulin and glucagon secretion in response to carbohydrate meal ingestion in healthy
individuals (Normal). An increased plasma glucose (left) following meal evokes insulin secretion from the b cells (middle); insulin secretion in individuals with
T2DM is reduced (red-dotted line). Glucagon secretion is normally suppressed by the elevation of plasma glucose (right; blue line). In diabetic patients, the
suppressor effect of glucose is reduced, and it may even stimulate glucagon release (right; red line). Data adapted from Dunning and Gerich (2007).mice. Thus, hyperinsulinemia was unable
to suppress glucagon secretion in the
mutants to the same extent as in the
controls, most likely because of the loss
of a cell insulin receptors. However, the
finding that hypoglycemia remains a strong
stimulus (>3-fold) of glucagon secretion in
the wild-type mice in this experimental
paradigm (when insulin is permanently
increased to high concentrations) cannot
easily be reconciled with the notion of
insulin as the sole major determinant of
glucagon secretion; if this were the case
then glucagon secretion should decrease
(not increase) when insulin was applied.
Clearly, hypoglycemia itself has the
capacity of overriding the inhibitory effect
of insulin on glucagon secretion. The pres-
ence of an intrinsic a cell regulation of
glucagon secretion is also suggested by304 Cell Metabolism 9, April 8, 2009 ª2009 Ethe fact that most of the modulation of
glucose occurs at glucose concentrations
without stimulatory effect on insulin secre-
tion (Vieira et al., 2007; MacDonald et al.,
2007). This is an important result, and this
study (as is often the case with good
science) provides insights that perhaps
extend beyond its original objective.
Finally, it should be remembered that
ablation of insulin signaling may also influ-
ence a cell function by long-term effects.
Such effects may be exerted via changes
in gene transcription (as has been docu-
mented in b cells; Leibiger and Berggren,
2008) that affect the levels of ion channels
and metabolic enzymes in a way that
results in increased a cell activity and
glucagon secretion. The aIRKO mouse
represents a very valuable tool in the future
endeavors to disentangle the complexlsevier Inc.mechanisms involved in the short- as
well as long-term regulation of glucagon
secretion. Modulation of a cell function
and glucagon secretion provides attrac-
tive therapeutic approaches for improving
glucose homeostasis in patients with all
forms of diabetes.
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Nutrient availability can have major effects
on growth, development, and metabolism.
There are complex interactions between
diet composition, caloric intake, environ-
ment, and genotype in the control of
health, aging, and longevity. The ability of
an organism to sense, acquire, and effi-
ciently process energy (nutrients) is crucial
for its health and survival. Within the cell,
changes in energy status (or cellular
stress) alter NAD+ and AMP. These levels
serve as intracellular energy indicators
that lead to the modulation of metabolic
pathways through a complex network of
regulatory proteins that ultimately influ-
ence gene regulation in response to the
existing energy status. In part, this gene
regulation is driven by histone acetyl-
transferases (HATs) and histone deacety-
lases (HDACs), a family of enzymes that
regulate (de)acetylation homeostasis
within the nucleus. A paper published this
week in Cell by Lin et al. (2009) demon-
strates that elevated levels of acetyl-
CoA (acCoA) concentration favor the
transcription of phosphoenolpyruvate
carboxykinase (PCK1) and the stimula-
tory acetylation of Pck1p by the nucleo-
some acetyltransferase (NuA4) and, in
turn, regulate yeast chronological life
span (CLS) (Figure 1).McGuiness, O.P., and Kulkarni, R.N. (2009). Cell
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Mounting evidence supports that many
aging processes are regulated by energy
metabolism, including NAD+ biosynthesis
(Yang et al., 2007), NAD+-dependent sir-
tuin deacetylation of histones or PGC-1a
(Schwer and Verdin, 2008), and the transi-
tion between glycolysis and respiration
by Nqr1 (Jime´nez-Hidalgo et al., 2009).
All these mechanisms are dependent on
nutrient availability and clearly demon-
strate the importance of equilibrium
between the uptake and efficient pro-
cessing of energy. Efficient and balanced
energy metabolism leads to increases in
both mean and maximum life span, ulti-
mately leading to healthy aging. Most of
these discoveries were made in yeast,
due to the ease of genetic manipulation
and ability to transition from fermentation
to respiration during normal growth
conditions as glucose concentrations fall
in growth media. Using this model, Lin
et al. (2009) report that Pck1 regulates
yeast CLS. This effect is regulated by
acetylation of PCK1 by the acCoA-depen-
dent NuA4 complex and deacetylation by
NAD+-dependent Sir2. The effect of Sir2
on CLS is mediated by inactivation of
alcohol dehydrogenase 2 (Adh2) that
uses the ethanol produced by fermenta-
tion (Fabrizio et al., 2005).
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gulated by acetyl-CoA. This finding
In recent years, the regulation of chro-
matin-associated proteins by acetylation
has been reported as a key regulatory
mechanism in gene regulation (Yang and
Seto, 2008), but there is little to no infor-
mation on the role of acetylation on cyto-
solic enzymes. Pck1 is unique to the
gluconeogenesis pathway in that it cata-
lyzes the formation of phosphoenolpyr-
uvate from oxaloacetate. Gluconeogen-
esis is activated when yeast has access
only to nonfermentable carbon sources
or by starvation and results in the syn-
thesis of glucose-6-phosphate, required
for both nucleotide and aromatic amino
acid biosynthesis. The balance between
glycolysis and gluconeogenesis is impor-
tant to maintain the bioenergetics of aero-
bic metabolism. In fact, it is known that
transformation of pyruvate to oxaloace-
tate by pyruvate carboxylase is activated
by acCoA and inhibited by ADP (Pronk
et al., 1996).
The paper by Lin et al. (2009) identifies
Pck1 as an extranuclear, nonhistone
substrate of NuA4 acetylation using
acCoA, connecting nutrient availability,
energy status, and survival. In other
words, this paper connects (de)acetyla-
tion and metabolic control via extranu-
clear actions of HATs and HDACs,
lism 9, April 8, 2009 ª2009 Elsevier Inc. 305
